Is Pharvaris NV halal to invest in?

According to Musaffa's Shariah screening methodology, Pharvaris NV (PHVS) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Pharvaris NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Pharvaris NV using these criteria to determine its compliance status.

Can Muslims buy shares of Pharvaris NV?

Muslim investors may consider investing in Pharvaris NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Pharvaris NV classified as NOT HALAL?

Musaffa determines the Shariah status of Pharvaris NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Pharvaris NV updated?

The Shariah compliance status of Pharvaris NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Pharvaris NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Pharvaris NV?

You can check the latest Shariah compliance status of Pharvaris NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

PHVS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 16, 2026

Report Source: 2025 Annual Report

Pharvaris NV. Stock Analysis PHVS

United States Health Care Small Cap Report: 2025 Annual

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 129 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Key Statistics of Pharvaris NV (PHVS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$29.36$30.44

Today's Open

$30.34

Volume

444.23K

P/E Ratio (TTM)

52 Week Range

$15.34$33.33

Market Cap

1.92B

Avg. Volume

362.68K

Dividend Yield

Financial Metrics & Statements of Pharvaris NV (PHVS)

FAQ's for Pharvaris NV (PHVS)

According to Musaffa’s Shariah screening methodology, Pharvaris NV (PHVS) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.